InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and effi..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 5.
  • textsms

J&J settles Stelara issue with Teva, Alvotech

Johnson & Johnson (J&J) has settled with Teva and Alvotech over the biosimilar to its most lucrative asset, Stelara. The deal allows AVT04 to enter the US market no later than February 2025. This follows a May 2023 agreement with Amgen over ABP 654, which will hit markets no later than January 1, 2025. Stelara is a human IgG1k monoclonal antibody that targets the IL-12 and IL-23 cytokines. Its p..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 14.
  • textsms